Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

ESSA Pharma Inc. (EPIX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.70+0.07 (+1.24%)
At close: 04:00PM EDT
5.70 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close5.63
Open5.61
Bid5.70 x 800
Ask6.90 x 1000
Day's Range5.22 - 5.74
52 Week Range5.22 - 36.00
Volume111,602
Avg. Volume255,855
Market Cap251.14M
Beta (5Y Monthly)1.57
PE Ratio (TTM)N/A
EPS (TTM)-0.87
Earnings DateAug 15, 2022 - Aug 19, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.40
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for EPIX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ESSA Pharma Inc.
    Daily – Vickers Top Insider Picks for 05/19/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • CNW Group

    ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022

    ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2022. All references to "$" in this release refer to United States dollars, unless otherwise indicated.

  • PR Newswire

    ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

    ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the 2022 Bloom Burton & Co. Healthcare Investor Conference on Monday, May 2, 2022 at 2:30 p.m. Eastern Time.

  • Zacks Small Cap Research

    EPIX: Preclinical Data on Androgen Receptor N-Terminal Domain Degrader Presented at AACR…

    By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Data on First Generation Androgen Receptor N-Terminal Degrader Presented at AACR 2022 On April 8, 2022, ESSA Pharma, Inc. (NASDAQ:EPIX) announced that preclinical data for the company’s first-generation androgen receptor (AR) ANITen bAsed Chimera (ANITAC™) N-terminal domain (NTD) degraders was presented at the 2022

Advertisement
Advertisement